Mereo BioPharma Group (MREO) Stock Forecast, Price Target & Predictions
MREO Stock Forecast
Mereo BioPharma Group stock forecast is as follows: an average price target of $6.75 (represents a 81.45% upside from MREO’s last price of $3.72) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
MREO Price Target
The average price target for Mereo BioPharma Group (MREO) is $6.75 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $4.00. This represents a potential 81.45% upside from MREO's last price of $3.72.
MREO Analyst Ratings
According to 2 Wall Street analysts, Mereo BioPharma Group's rating consensus is 'Buy'. The analyst rating breakdown for MREO stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Mereo BioPharma Group Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 20, 2024 | Joseph Schwartz | Leerink Partners | - | - | 101.01% | 115.05% |
| Jun 12, 2024 | Jack Allen | Robert W. Baird | - | - | 108.88% | 115.05% |
| Jun 12, 2024 | Gil Blum | Needham | - | - | 98.86% | 88.17% |
| Mar 28, 2024 | Gil Blum | Needham | - | - | 100.00% | 61.29% |
| Aug 12, 2022 | Cantor Fitzgerald | - | - | 196.30% | 7.53% |
The latest Mereo BioPharma Group stock forecast, released on Jun 20, 2024 by Joseph Schwartz from Leerink Partners, set a price target of $8.00, which represents a 101.01% increase from the stock price at the time of the forecast ($3.98), and a 115.05% increase from MREO last price ($3.72).
Mereo BioPharma Group Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $7.25 |
| Last Closing Price | $3.72 | $3.72 | $3.72 |
| Upside/Downside | -100.00% | -100.00% | 94.89% |
In the current month, the average price target of Mereo BioPharma Group stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Mereo BioPharma Group's last price of $3.72. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 12, 2024 | Needham | Buy | Buy | Hold |
| Mar 28, 2024 | Needham | Buy | Buy | Hold |
| Aug 12, 2022 | Cantor Fitzgerald | Overweight | Initialise | |
| Jun 06, 2022 | Needham | Buy | Buy | Hold |
| Mar 17, 2022 | Needham | Buy | Buy | Hold |
| Apr 05, 2021 | Needham | Buy | Initialise |
Mereo BioPharma Group's last stock rating was published by Needham on Jun 12, 2024. The company gave MREO a "Buy" rating, the same as its previous rate.
Mereo BioPharma Group Financial Forecast
Mereo BioPharma Group Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | $14.78M | $11.04M | $28.57M | - | $19.75M | $3.27M |
| High Forecast | - | - | $14.78M | $11.04M | $28.57M | - | $19.75M | $3.27M |
| Low Forecast | - | - | $14.78M | $11.04M | $28.57M | - | $19.75M | $3.27M |
| # Analysts | - | - | 3 | 5 | 5 | - | 4 | 3 |
| Surprise % | - | - | - | - | - | - | - | - |
Mereo BioPharma Group's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. MREO's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Mereo BioPharma Group EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 3 | 5 | 5 | - | 4 | 3 |
| EBITDA | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | $-6.32M | $-4.72M | $-12.21M | - | $-8.44M | $-1.67M |
| High Forecast | - | - | $-6.32M | $-4.72M | $-12.21M | - | $-8.44M | $-1.67M |
| Low Forecast | - | - | $-6.32M | $-4.72M | $-12.21M | - | $-8.44M | $-1.67M |
| Surprise % | - | - | - | - | - | - | - | - |
undefined analysts predict MREO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Mereo BioPharma Group's previous annual EBITDA (undefined) of $NaN.
Mereo BioPharma Group Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 3 | 5 | 5 | - | 4 | 3 |
| Net Income | - | - | - | - | - | - | - | - |
| Avg Forecast | $-9.71M | $-7.28M | $-1.21M | $-1.21M | $6.07M | $-10.36M | $-6.08M | $-58.24M |
| High Forecast | $-9.71M | $-7.28M | $-1.21M | $-1.21M | $41.17M | $-10.36M | $-6.08M | $-58.24M |
| Low Forecast | $-9.71M | $-7.28M | $-1.21M | $-1.21M | $-8.45M | $-10.36M | $-6.08M | $-58.24M |
| Surprise % | - | - | - | - | - | - | - | - |
Mereo BioPharma Group's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MREO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Mereo BioPharma Group SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 3 | 5 | 5 | - | 4 | 3 |
| SG&A | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | $-180.76M | $-134.97M | $-349.47M | - | $-241.56M | $-40.03M |
| High Forecast | - | - | $-180.76M | $-134.97M | $-349.47M | - | $-241.56M | $-40.03M |
| Low Forecast | - | - | $-180.76M | $-134.97M | $-349.47M | - | $-241.56M | $-40.03M |
| Surprise % | - | - | - | - | - | - | - | - |
Mereo BioPharma Group's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to MREO last annual SG&A of $NaN (undefined).
Mereo BioPharma Group EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 3 | 5 | 5 | - | 4 | 3 |
| EPS | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.01 | $-0.01 | $-0.00 | $-0.00 | $0.01 | $-0.01 | $-0.01 | $-0.41 |
| High Forecast | $-0.01 | $-0.01 | $-0.00 | $-0.00 | $0.05 | $-0.01 | $-0.01 | $-0.41 |
| Low Forecast | $-0.01 | $-0.01 | $-0.00 | $-0.00 | $-0.01 | $-0.01 | $-0.01 | $-0.41 |
| Surprise % | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Mereo BioPharma Group's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MREO previous annual EPS of $NaN (undefined).
Mereo BioPharma Group Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | - | - | 10506.06% | Buy |
| ELEV | Elevation Oncology | - | - | 1400.00% | Buy |
| XFOR | X4 Pharmaceuticals | - | - | 979.41% | Buy |
| INZY | Inozyme Pharma | - | - | 422.06% | Buy |
| PDSB | PDS Bio | - | - | 330.62% | Buy |
| ABOS | Acumen Pharmaceuticals | - | - | 195.36% | Buy |
| DAWN | Day One Biopharmaceuticals | - | - | 182.80% | Buy |
| TERN | Terns Pharmaceuticals | - | - | 146.11% | Buy |
| MREO | Mereo BioPharma Group | - | - | 81.45% | Buy |
| HOOK | HOOKIPA Pharma | - | - | 39.53% | Buy |
| AMLX | Amylyx Pharmaceuticals | - | - | 26.57% | Buy |
| EFTR | eFFECTOR Therapeutics | - | - | - | Buy |